Related Experiment Video

Updated: Aug 25, 2026

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

Increased risk for Alzheimer disease with the interaction of MPO and A2M polymorphisms

Mario Zappia1, Ida Manna, Paolo Serra

  • 1Institute of Neurology, University Magna Graecia, Catanzaro, Italy.

Archives of Neurology
|March 17, 2004
PubMed
Abstract

Insights

Genetic variations in myeloperoxidase (MPO) and alpha(2)-macroglobulin (A2M) are linked to Alzheimer's disease (AD) risk. Combined MPO and A2M gene variants significantly increase the likelihood of developing sporadic AD in southern Italy.

Area of Science:

  • Genetics
  • Neuroscience
  • Molecular Biology

Background:

  • Myeloperoxidase (MPO) and alpha(2)-macroglobulin (A2M) genes are implicated in beta-amyloid deposition pathways relevant to Alzheimer's disease (AD).
  • Previous studies on MPO-G/A and A2M-Ile/Val polymorphisms and AD risk have yielded conflicting results across different ethnic groups.

Purpose of the Study:

  • To investigate the association between MPO-G/A and A2M-Ile/Val polymorphisms and sporadic AD.
  • To explore potential interactions between MPO, A2M, and apolipoprotein E (APOE) gene polymorphisms in AD risk.

Main Methods:

  • A case-control study was conducted.
  • Participants included 148 patients with sporadic AD and 158 healthy controls from a referral center in Calabria, southern Italy.

Main Results:

  • The MPO-G and A2M-Val alleles and their respective MPO-G/G and A2M-Val/Val genotypes were more prevalent in AD cases than controls.
  • The MPO-G/G genotype showed an odds ratio (OR) of 1.78, and the A2M-Val/Val genotype had an OR of 3.81.
  • A synergistic interaction between MPO-G/G and A2M-Val/Val genotypes significantly elevated AD risk (OR, 25.5).

Conclusions:

  • MPO and A2M polymorphisms are associated with sporadic AD in the southern Italian population.
  • A significant genomic interaction between MPO and A2M polymorphisms amplifies the risk of developing Alzheimer's disease.

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...